Drugs / IX-01
Trials 5
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 14 trials | ||||||
| Phase 1 | NCT02962531 | Nov → Dec 2016 | — | Ixchelsis Limited | Completed | No outcome recorded |
| Phase 1 | NCT02792647 | May → Jul 2016 | — | Ixchelsis Limited | Completed | No outcome recorded |
| Phase 1 | NCT02139826 | May → Jun 2014 | — | Ixchelsis Limited | Completed | No outcome recorded |
| Phase 1 | NCT01994083 | Nov 2013 → Mar 2014 | — | Ixchelsis Limited | Completed | No outcome recorded |
| Phase 21 trial · 1 missed | ||||||
| Phase 2 | NCT03055806 | Feb → Nov 2017 | premature ejaculation | Ixchelsis Limited | Completed | Missed primary |
Evidence & citations 3 cited values
Every value below carries the sentence it was read from. 6 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | IX-01 | ClinicalTrials.gov intervention name — accepted as the source's own label NCT02139826 ↗ |
| Action | Inhibit | “cligosiban, an oxytocin antagonist” PMID 31351660 ↗ Aug 2019 |
| Route | Oral | “Administered orally” NCT01994083 ↗ |